Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CCKBR | P32239 | 7/20 | 0.47 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020893 | 0.83 | CASP1 (0.54) | CASP1CASP3CASP7 | |
| SCHEMBL14417484 | 0.83 | CASP1 (0.54) | CASP1CASP3CASP7 | |
| SCHEMBL29437935 | 0.81 | DPP3 (0.58) | DPP3CAPN1CTSBCCKBROPRM1 | |
| SCHEMBL13021030 | 0.81 | GHSR (0.49) | CASP1CASP3CASP7 | |
| SCHEMBL13912385 | 0.81 | GHSR (0.49) | CASP1CASP3CASP7 | |
| SCHEMBL29437939 | 0.81 | CAPN1 (0.60) | DPP3CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL13020158 | 0.80 | CASP1 (0.51) | CCKBRCCKAROPRM1CASP1CASP3 | |
| SCHEMBL30477480 | 0.80 | CAPN1 (0.65) | DPP3CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL29437937 | 0.80 | CAPN1 (0.63) | DPP3CAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL30224116 | 0.80 | CAPN1 (0.64) | DPP3CAPN1CTSBNTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323969-A1 | Compounds Binding to P-Selectin | ASTELLAS PHARMA EUROPE B.V. (NL) | 2010-12-23 | — | — | US | disclosed |
| US-20090062186-A1 | Compounds Binding To P-Selectin | YAMANOUCHI ERUOPE B.V. (NL) | 2009-03-05 | — | — | US | disclosed |
| US-20090062186-A1 | Compounds Binding To P-Selectin | YAMANOUCHI ERUOPE B.V. (NL) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062186-A1 | Compounds Binding To P-Selectin | SELP, SELPLG, SELL | DPP3 546/4885CAPN1 3266/4885CTSB 1804/4885 |
| US-20100323969-A1 | Compounds Binding to P-Selectin | SELP, SELPLG, SELL | DPP3 546/4885CAPN1 3266/4885CTSB 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.